Palbociclib (breast cancer, combination with an aromatase inhibitor) – Addendum to Commission A22-66

Report documents

1. Addendum

   Palbociclib (breast cancer, combination with an aromatase inhibitor) – Addendum to Commission A22-66

   published on

   15.12.2022

   Document type

   PDF document, 481 kB, EN, not accessible

   Download file : Addendum (PDF document, 481 kB, EN, not accessible)

Additional information

Project details

Project no.

A22-120

Commission

Commission awarded on 08.11.2022 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Drug Assessment

Topic

Cancer

Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

1. Dossier assessment

   Palbociclib (breast cancer) – Benefit assessment according to § 35a SGB V

   Project no.

   A22-66

   Last updated

   15.12.2022

   Status: Commission completed